secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001564590-21-041660
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q2 revenue $20.7M (+167% YoY); raises FY2021 guidance to $90-95M
-------------------------------------------------------------------------------

- Revenue $20.7M, up 167% from $7.7M in Q2 2020; gross margin improved to 80.9% from 73.1%.
- Net loss of ($5.1M) or ($0.10) per share, compared to ($2.1M) loss a year ago.
- Cash and equivalents $119.6M, including $107.6M from April 2021 IPO.
- FY2021 revenue guidance raised to $90-95M (57-65% growth) from prior $87-92M.
- ALIGN3D clinical study shows positive radiographic and patient-reported outcomes from 6 weeks to 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000156459021041660/0001564590-21-041660-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000156459021041660/tmci-8k_20210805.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-041660

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer